# Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

> **NCT03201757** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 523 (actual)

## Conditions studied

- Schizophrenia
- Schizophreniform Disorder
- Bipolar I Disorder

## Interventions

- **DRUG:** ALKS 3831

## Key facts

- **NCT ID:** NCT03201757
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-15
- **Primary completion:** 2023-09-06
- **Final completion:** 2023-09-06
- **Target enrollment:** 523 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201757, "Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03201757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*